Qube Research & Technologies Ltd purchased a new position in shares of Catalent Inc (NYSE:CTLT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,116 shares of the company’s stock, valued at approximately $277,000.
Other hedge funds also recently modified their holdings of the company. Swiss National Bank boosted its stake in shares of Catalent by 2.3% in the second quarter. Swiss National Bank now owns 270,970 shares of the company’s stock valued at $14,689,000 after purchasing an additional 6,000 shares during the period. Comerica Bank boosted its stake in Catalent by 2.7% during the 2nd quarter. Comerica Bank now owns 97,548 shares of the company’s stock valued at $5,244,000 after acquiring an additional 2,527 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Catalent by 4.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 106,302 shares of the company’s stock valued at $5,763,000 after acquiring an additional 4,837 shares during the last quarter. Advisory Services Network LLC boosted its stake in Catalent by 115.5% during the 2nd quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after acquiring an additional 395 shares during the last quarter. Finally, TD Asset Management Inc. boosted its stake in Catalent by 7.4% during the 2nd quarter. TD Asset Management Inc. now owns 500,816 shares of the company’s stock valued at $27,149,000 after acquiring an additional 34,571 shares during the last quarter. 99.94% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have commented on CTLT shares. Jefferies Financial Group upgraded shares of Catalent from a “hold” rating to a “buy” rating and increased their price objective for the company from $50.00 to $62.00 in a research note on Friday, June 21st. UBS Group increased their price objective on shares of Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the company. Catalent presently has an average rating of “Buy” and a consensus target price of $55.14.
Shares of NYSE:CTLT traded down $0.17 on Wednesday, reaching $55.60. 2,193 shares of the company’s stock were exchanged, compared to its average volume of 644,031. The firm has a market capitalization of $8.14 billion, a price-to-earnings ratio of 35.18, a PEG ratio of 2.74 and a beta of 1.64. Catalent Inc has a fifty-two week low of $29.23 and a fifty-two week high of $58.38. The business’s 50-day moving average is $55.44 and its two-hundred day moving average is $47.05. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.